Singular Genomics Systems (NASDAQ:OMIC – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Institutional and Insider Ownership

56.3% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 45.3% of Nautilus Biotechnology shares are owned by institutional investors. 22.6% of Singular Genomics Systems shares are owned by company insiders. Comparatively, 41.3% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Singular Genomics Systems has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Profitability

Valuation & Earnings

This table compares Singular Genomics Systems and Nautilus Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Singular Genomics Systems and Nautilus Biotechnology, as provided by MarketBeat.

Singular Genomics Systems currently has a consensus target price of $3.50, indicating a potential upside of 33.59%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 100.00%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Singular Genomics Systems.

Summary

Nautilus Biotechnology beats Singular Genomics Systems on 7 of the 10 factors compared between the two stocks.

About Singular Genomics Systems

(Get Rating)

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.

About Nautilus Biotechnology

(Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.